Sarepta stock faces FDA scrutiny after liver failure deaths

The U.S. FDA is investigating deaths from acute liver failure in non-ambulatory Duchenne muscular dystrophy patients treated with Sarepta Therapeutics’ ELEVIDYS, following reports from both clinical trial and post-marketing data. The agency is "evaluating the need for further regulatory action" given the current prescribing information does not specifically warn of liver failure or death. This development presents a significant regulatory challenge for Sarepta, with H.C. Wainwright maintaining a Sell rating and expecting updated label language, compounding prior FDA criticism of the drug's approval.

Analysis

Sarepta Therapeutics (SRPT) faces a significant regulatory headwind following the U.S. FDA's announcement of an investigation into patient deaths from acute liver failure linked to its Duchenne muscular dystrophy (DMD) treatment, ELEVIDYS. The inquiry, prompted by a second reported death in a non-ambulatory pediatric patient, encompasses data from both clinical trials and post-marketing surveillance, adding weight to the safety concern. The FDA is now formally "evaluating the need for further regulatory action," a critical development given the current U.S. prescribing information warns of acute serious liver injury but not the more severe outcomes of liver failure or death. This situation is further compounded by the pre-existing controversy surrounding the drug's approval, which had drawn criticism from senior FDA officials. The market's negative perception is reinforced by H.C. Wainwright's reiterated "Sell" rating and $10.00 price target, with the firm anticipating that the FDA will likely mandate a label update to explicitly state the risk of liver failure or death.

Key Decisions for Investors

• Investors should anticipate heightened stock volatility and closely monitor any FDA communications regarding "further regulatory action," as a mandated label change to include liver failure or death could materially impact ELEVIDYS's commercial prospects.
• The new safety investigation exacerbates the risk profile for Sarepta, validating a bearish thesis as highlighted by H.C. Wainwright's 'Sell' rating and reinforcing concerns that stemmed from the drug's already controversial approval process.
• Given the severity of the adverse events reported from both clinical and post-marketing data, it is prudent for investors to re-evaluate their exposure to SRPT, as the potential regulatory fallout presents a substantial near-term risk to the company's valuation.